Copy Link Print Information

SAR405

35 Cited Publications
Customer Review

Based on 35 publication(s) in Google Scholar

SAR405 is a first-in-class, selective, and ATP-competitive PI3K class III (PIK3C3) isoform Vps34 inhibitor (IC50=1.2 nM; Kd=1.5 nM). SAR405 inhibits autophagy induced either by starvation or by mTOR inhibition. Anticancer activity.

For research use only. We do not sell to patients.

  • Purity: 99.74%
  • CAS No.: 1523406-39-4
  • Formula: C19H21ClF3N5O2
  • Molecular Weight:443.85
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • SAR405 Chemical Structure
    SAR405 Chemical Structure
  • Experimental Validation Results for SAR405
  • Experimental Validation Results for SAR405
  • Experimental Validation Results for SAR405
  • Experimental Validation Results for SAR405
  • Experimental Validation Results for SAR405
CAS No.: 1523406-39-4
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of SAR405:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) SAR405

More
Customer Validation & Images
IFIn Vivo Efficacy StudyRT-PCRWB
  • IF
  • RT-PCR
  • In Vivo Efficacy Study
  • WB
  • WB

All PI3K Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • SAR405 Chemical Structure
    SAR405 Chemical Structure
    1/16
  • 1/16

    SAR405 purchased from MedChemExpress. Usage Cited in: Nat Genet. 2021 Apr;53(4):435-444. [Abstract]

    Customer Validation
     Immunofluorescence staining of LC3B in uninfected or SARS-CoV-2-infected Huh7 cells treated with SAR405 (12.5 μM; 6 h) showed that PI3K type 3 inhibition completely abolished the formation of LC3-positive puncta and induced vacuoles in treated cells.

  • 1/16

    SAR405 purchased from MedChemExpress. Usage Cited in: Nat Genet. 2021 Apr;53(4):435-444. [Abstract]

    Customer Validation
     Time series experiments showed an early stage post-receptor binding effect of the PI3K type 3 inhibitor SAR405 on HCoV-229E infection. Huh7 cells were infected, treated with SAR405 at different timepoints, and followed by determination of viral RNA levels at 10 hours post infection by qPCR. Inhibition of HCoV-229E by SAR405 occurred later in the viral life cycle than the attachment stage, as benchmarked by the attachment inhibitor Urtica dioica agglutinin (UDA), but earlier than the onset of intracellular replication as identified using the viral RNA synthesis inhibitor remdesivir.

  • 1/16

    SAR405 purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2021 Aug;18(8):2024-2039. [Abstract]

    Customer Validation
     PIK3C3 was an important regulator of myeloid cell function and a potential therapeutic target for treating EAE. SAR405 treatment delayed the onset of EAE. EAE was induced by active immunization with MOG35–55 peptide, and SAR405 (10 mg/kg; once daily) was administered orally starting 3 days after immunization for 11 consecutive days.

  • 1/16

    SAR405 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):793-805. [Abstract]

    Customer Validation
     Serum-starved H4IIEC3 cells are treated with 100 nM ins for 0, 5, 15, and 30 min, and electrophoresed protein extracts subjected to western blotting using antibodies against pAktS473 and Akt.

  • 1/16

    SAR405 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):793-805. [Abstract]

    Customer Validation
     Serum-starved H4IIEC3 cells are treated with 100 nM ins for 0, 5, 15, and 30 min and electrophoresed protein extracts subjected to western blotting using antibodies against total or phosphorylated p42/p44 MAPK.

  • SAR405